Peripheral immune biomarkers and neurodegenerative diseases: a prospective cohort study with 20 years of follow‐up

S Yazdani, D Mariosa, N Hammar… - Annals of …, 2019 - Wiley Online Library
S Yazdani, D Mariosa, N Hammar, J Andersson, C Ingre, G Walldius, F Fang
Annals of neurology, 2019Wiley Online Library
Objective To assess the associations of several blood immune biomarkers with the future
risks of amyotrophic lateral sclerosis and Parkinson disease in a prospective cohort study
with 20 years of follow‐up. Methods The Swedish Apolipoprotein‐Related Mortality Risk
study is a longitudinal cohort study including 812,073 participants with repeated blood
biomarker measurements between 1985 and 1996 and a follow‐up until 2011. Using a Cox
model, we first estimated hazard ratios of amyotrophic lateral sclerosis and Parkinson …
Objective
To assess the associations of several blood immune biomarkers with the future risks of amyotrophic lateral sclerosis and Parkinson disease in a prospective cohort study with 20 years of follow‐up.
Methods
The Swedish Apolipoprotein‐Related Mortality Risk study is a longitudinal cohort study including 812,073 participants with repeated blood biomarker measurements between 1985 and 1996 and a follow‐up until 2011. Using a Cox model, we first estimated hazard ratios of amyotrophic lateral sclerosis and Parkinson disease in relation to leukocytes, immunoglobulin G, haptoglobin, and uric acid. We further described the temporal changes of these biomarkers during the 20 years prior to the diagnosis of these diseases.
Results
A total of 585 incident cases of amyotrophic lateral sclerosis and 3,769 incident cases of Parkinson disease were identified during the follow‐up. Increasing concentrations of leukocytes, haptoglobin, and uric acid were associated with a lower risk of Parkinson disease. No statistically significant association was, however, noted between the studied biomarkers and amyotrophic lateral sclerosis. Parkinson disease patients appeared to have lower levels of leukocytes and haptoglobin between 20 and 10 years before diagnosis and lower levels of uric acid during the 20 years before diagnosis, compared to controls, although statistically significant differences were only noted during parts of the respective time intervals after multivariable adjustment. No clear differences were noted between patients with amyotrophic lateral sclerosis and controls.
Interpretation
If verified in studies of independent populations, our findings may suggest a different role of systemic inflammation on the risk of Parkinson disease compared to amyotrophic lateral sclerosis. ANN NEUROL 2019;86:913–926
Wiley Online Library